Patents by Inventor Marc Lopez

Marc Lopez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL ANTI-NECTIN-4 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
    Publication number: 20260062481
    Abstract: The present invention relates to novel anti Nectin-4 antibodies and antibody-drug conjugates comprising these antibodies, as well as to the use thereof.
    Type: Application
    Filed: July 20, 2023
    Publication date: March 5, 2026
    Inventors: Jack ELANDS, Florence LHOSPICE, Marc LOPEZ, Daniel OLIVE, Xavier PREVILLE
  • ANTIBODY DRUG CONJUGATE (ADC) TARGETING NECTIN 4 AND COMPRISING AN EXATECAN PAYLOAD
    Publication number: 20260021194
    Abstract: The present disclosure provides Nectin-4 antibody drug conjugates (ADCs) comprising exatecan and pharmaceutical compositions thereof, and methods of using the ADCs for the treatment of cancer.
    Type: Application
    Filed: July 31, 2025
    Publication date: January 22, 2026
    Inventors: Jacobus Petrus Maria ELANDS, Joanna FARES, Guy FOURNET, Benoit JOSEPH, Florence LHOSPICE, Marc LOPEZ, Daniel OLIVE, Xavier PREVILLE, Warren VIRICEL
  • Antibody drug conjugate (ADC) targeting Nectin 4 and comprising an exatecan payload
    Patent number: 12419964
    Abstract: The present disclosure provides Nectin-4 antibody drug conjugates (ADCs) comprising exatecan and pharmaceutical compositions thereof, and methods of using the ADCs for the treatment of cancer.
    Type: Grant
    Filed: October 2, 2024
    Date of Patent: September 23, 2025
    Assignees: ELI LILLY AND COMPANY, UNIVERSITÉ D'AIX-MARSEILLE, INSERM (Institut National De La Sante Et De La Recherche Medicale), INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS, MABLINK BIOSCIENCE, UNIVERSITE CLAUDE BERNARD LYON
    Inventors: Jacobus Petrus Maria Elands, Joanna Fares, Guy Fournet, Benoit Joseph, Florence Lhospice, Marc Lopez, Daniel Olive, Xavier Preville, Warren Viricel
  • Antibodies having specificity for nectin-4 and uses thereof
    Patent number: 12398206
    Abstract: The present invention relates to antibodies having specificity for Nectin-4 and uses thereof, in particular for the treatment of cancer.
    Type: Grant
    Filed: October 7, 2020
    Date of Patent: August 26, 2025
    Assignees: UNIVERSITÉ D'AIXMARSEILLE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS
    Inventors: Marc Lopez, Daniel Olive
  • ANTIBODY DRUG CONJUGATE (ADC) TARGETING NECTIN 4 AND COMPRISING AN EXATECAN PAYLOAD
    Publication number: 20250127916
    Abstract: The present disclosure provides Nectin-4 antibody drug conjugates (ADCs) comprising exatecan and pharmaceutical compositions thereof, and methods of using the ADCs for the treatment of cancer.
    Type: Application
    Filed: October 2, 2024
    Publication date: April 24, 2025
    Inventors: Jacobus Petrus Maria ELANDS, Joanna FARES, Guy FOURNET, Benoit JOSEPH, Florence LHOSPICE, Marc LOPEZ, Daniel OLIVE, Xavier PREVILLE, Warren VIRICEL
  • ANTI-NECTIN-4-ANTIBODIES AND USES THEREOF
    Publication number: 20250018053
    Abstract: The present invention relates to antibodies having specificity to Nectin-4 and uses thereof.
    Type: Application
    Filed: June 17, 2024
    Publication date: January 16, 2025
    Inventors: Jack ELANDS, Florence L'HOSPICE, Marc LOPEZ, Daniel OLIVE, Xavier PRÉVILLE
  • Anti-nectin-4-antibodies and uses thereof
    Patent number: 12049500
    Abstract: The present invention relates to antibodies having specificity to Nectin-4 and uses thereof.
    Type: Grant
    Filed: March 31, 2022
    Date of Patent: July 30, 2024
    Assignees: EMERGENCE THERAPEUTICS GmbH, UNIVERSITE D'AIX-MARSEILLE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS-
    Inventors: Jack Elands, Florence L'Hospice, Xavier Préville, Daniel Olive, Marc Lopez
  • ANTI-NECTIN-4 ANTIBODY AMANITIN CONJUGATES
    Publication number: 20240181075
    Abstract: The present invention relates to an antibody-drug conjugate comprising a monoclonal antibody or an antigen-binding fragment thereof wherein the monoclonal antibody or the antigen-binding fragment thereof binds to Nectin-4 and wherein the drug is an amatoxin, particularly ?-amanitin.
    Type: Application
    Filed: March 31, 2022
    Publication date: June 6, 2024
    Applicants: EMERGENCE THERAPEUTICS AG, UNIVERSITE D’AIX-MARSEILLE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE – CNRS
    Inventors: Jack ELANDS, Florence LHOSPPICE, Xavier PRÉVILLE, Daniel OLIVE, Marc LOPEZ
  • ANTI-NECTIN-4-ANTIBODY EXATECAN CONJUGATES
    Publication number: 20240173424
    Abstract: The present invention relates to an antibody -drug conjugate comprising a monoclonal antibody or an antigen-binding fragment thereof wherein the monoclonal antibody or the antigen-binding fragment thereof binds to Nectin-4 and wherein the drug is a topoisomerase I inhibitor, particularly exatecan.
    Type: Application
    Filed: March 31, 2022
    Publication date: May 30, 2024
    Applicants: EMERGENCE THERAPEUTICS AG, UNIVERSITE D’AIX-MARSEILLE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE – CNRS
    Inventors: Jack ELANDS, Florence LHOSPPICE, Xavier PRÉVILLE, Daniel OLIVE, Marc LOPEZ
  • ANTI-NECTIN-4-ANTIBODIES AND USES THEREOF
    Publication number: 20240034791
    Abstract: The present invention relates to antibodies having specificity to Nectin-4 and uses thereof.
    Type: Application
    Filed: March 31, 2022
    Publication date: February 1, 2024
    Applicants: EMERGENCE THERAPEUTICS AG, UNIVERSITE D’AIX-MARSEILLE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE – CNRS –
    Inventors: Jack ELANDS, Florence LHOSPPICE, Xavier PRÉVILLE, Daniel OLIVE, Marc LOPEZ
  • ANTIBODIES HAVING SPECIFICITY FOR NECTIN-4 AND USES THEREOF
    Publication number: 20230183337
    Abstract: The present invention relates to antibodies having specificity for Nectin-4 and uses thereof, in particular for the treatment of cancer.
    Type: Application
    Filed: October 7, 2020
    Publication date: June 15, 2023
    Inventors: Marc LOPEZ, Daniel OLIVE
  • Antibodies having specificity to Nectin-4 and uses thereof
    Patent number: 11274160
    Abstract: The present invention relates to a new antibody anti-nectin-4. Nectin-4 is a tumor-associated antigen overexpressed in several cancers and notably in 30%, 49% and 86% of breast, ovarian and lung carcinomas, respectively, which are tumors of bad prognosis. Treatments remain still elusive. That's why the inventors developed a new targeted therapy based on an antibody having specificity to nectin-4 (called 14A5.2 mab). Indeed, the inventors selected this antibody for its intrinsic prophylactic anti-metastatic properties and also for the treatment of localized primary and metastatic cancer. More, the 14A5.2 mab could be indicated for the treatment of cancer resistant to ASG-22ME (from Astellas company). Thus, the invention relates to the 14A5.2 mab and its uses thereof.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: March 15, 2022
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale, INSTITUT JEAN PAOLI & IRENE CALETTES, CENTRE NATIONALE DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE D'AIX MARSEILLE
    Inventor: Marc Lopez
  • ANTIBODIES HAVING SPECIFICITY TO NECTIN-4 AND USES THEREOF
    Publication number: 20210324104
    Abstract: The present invention relates to a new antibody anti-nectin-4. Nectin-4 is a tumor-associated antigen overexpressed in several cancers and notably in 30%, 49% and 86% of breast, ovarian and lung carcinomas, respectively, which are tumors of bad prognosis. Treatments remain still elusive. That's why the inventors developed a new targeted therapy based on an antibody having specificity to nectin-4 (called 14A5.2 mab). Indeed, the inventors selected this antibody for its intrinsic prophylactic anti-metastatic properties and also for the treatment of localized primary and metastatic cancer. More, the 14A5.2 mab could be indicated for the treatment of cancer resistant to ASG-22ME (from Astellas company). Thus, the invention relates to the 14A5.2 mab and its uses thereof.
    Type: Application
    Filed: March 1, 2018
    Publication date: October 21, 2021
    Inventor: Marc LOPEZ
  • Antibodies having specificity to nectin-4 and uses thereof
    Patent number: 10675357
    Abstract: The present invention relates to antibodies having specificity to nectin-4 and uses thereof.
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: June 9, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, UNIVERSITÉ D'AIX MARSEILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT JEAN PAOLI & IRENE CALMETTES
    Inventors: Marc Lopez, Daniel Olive
  • ANTIBODIES HAVING SPECIFICITY TO NECTIN-4 AND USES THEREOF
    Publication number: 20180243434
    Abstract: The present invention relates to antibodies having specificity to nectin-4 and uses thereof.
    Type: Application
    Filed: September 7, 2016
    Publication date: August 30, 2018
    Inventors: Marc LOPEZ, Daniel OLIVE
  • NOVEL ANTIGEN PEPTIDE AND USES THEREOF
    Publication number: 20160331818
    Abstract: The invention relates to antigen peptide derived from the Nectin4 and its use for preventing and treating cancer.
    Type: Application
    Filed: December 9, 2015
    Publication date: November 17, 2016
    Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), UNIVERSITE D'AIX MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTES
    Inventors: Marc LOPEZ, Daniel OLIVE
  • Antigen peptide and uses thereof
    Patent number: 9266922
    Abstract: The invention relates to antigen peptide derived from the Nectin4 and its use for preventing and treating cancer.
    Type: Grant
    Filed: May 31, 2012
    Date of Patent: February 23, 2016
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite d'Aix Marseille, Institut Jean Paoli & Irene Calmettes
    Inventors: Marc Lopez, Daniel Olive
  • Apoptosis inducing compounds
    Patent number: 9193699
    Abstract: Provided are compounds of formula (I): wherein R1, R2, R3, R4 and R5 are independently selected from the group comprising, inter aliae, H, optionally substituted, branched or linear C1-C12 alkyl, halogen atom and C1-C12 haloalkyl, and wherein A represents a single bond or an optionally substituted C1-C6 alkylene radical, notably useful for the treatment of human cancers.
    Type: Grant
    Filed: October 4, 2012
    Date of Patent: November 24, 2015
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.), UNIVERSITÉ D'AIX-MARSEILLE, L'INSTITUT PAOLI-CALMETTES
    Inventors: Marc Lopez, Yves Collette, Lynda Mezil, Jean-Michel Brunel, Sebastien Combes
  • APOPTOSIS INDUCING COMPOUNDS
    Publication number: 20140296227
    Abstract: The present invention relates to compounds of formula (I), wherein R1, R2, R3, R4 and R5 are independently selected from the group comprising, inter aliae, H, optionally substituted, branched or linear C1-C12 alkyl, halogen atom and C1-C12 haloalkyl, and wherein A represents a single bond or an optionally substituted C1-C6 alkylene radical, notably useful for the treatment of human neoplasms.
    Type: Application
    Filed: October 4, 2012
    Publication date: October 2, 2014
    Inventors: Marc Lopez, Yves Collette, Lynda Mezil, Jean-Michel Brunel, Sebastien Combes
  • NOVEL ANTIGEN PEPTIDE AND USES THEREOF
    Publication number: 20140178394
    Abstract: The invention relates to antigen peptide derived from the Nectin4 and its use for preventing and treating cancer.
    Type: Application
    Filed: May 31, 2012
    Publication date: June 26, 2014
    Applicants: UNIVERSITE D'AIX MARSEILLE, INSERM (Insititut Nationa de la Sante et de la Rec Recherche Medicals), INSTITUT JEAN PAOLI & IRENE CALMETTES
    Inventors: Marc Lopez, Daniel Olive